Silo Pharma (SILO) Cash from Financing Activities (2010 - 2025)

Silo Pharma has reported Cash from Financing Activities for 10 years, with the latest figure at $2.1 million in Q4 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.5 million (up 39.06% YoY) and the FY2025 annual result came in at $4.9 million, up 49.93% from the prior year.
• Cash from Financing Activities grew to $2.1 million in Q4 2025 per SILO's latest filing, from $634922.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.8 million in Q1 2021 and troughed at -$194423.0 in Q4 2023.
• A 4-year average of $1.1 million and a median of $634922.0 in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 25209.79% in 2021, down 100.11% in 2021.
• Over 4 years, Cash from Financing Activities stood at -$2366.0 in 2021, then sank by 8117.37% to -$194423.0 in 2023, then jumped by 995.74% to $1.7 million in 2024, then gained by 22.38% to $2.1 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.1 million, $634922.0, and $1.7 million for Q4 2025, Q3 2025, and Q3 2024 respectively.